Loading...
•
Mar 29
Thermo Fisher Q1 2025 Earnings Report
Thermo Fisher reported solid financial results with stable revenue and growth in GAAP EPS.
Key Takeaways
Thermo Fisher delivered a strong Q1 with slight revenue growth, improved GAAP EPS, and robust product innovation in semiconductor and precision medicine sectors.
Revenue reached $10.36 billion, up from $10.34 billion in Q1 2024.
GAAP EPS rose to $3.98 while adjusted EPS increased slightly to $5.15.
Net income improved to $1.51 billion from $1.33 billion a year ago.
Launched several innovative products including the Vulcan Automated Lab and Olink Reveal kits.
Thermo Fisher
Thermo Fisher
Thermo Fisher Revenue by Segment
Revenue by Segment
Life Sciences Solutions Revenue
CapyFin.comAnalytical Instruments Revenue
CapyFin.comSpecialty Diagnostics Revenue
CapyFin.comLaboratory Products and Biopharma Services Revenue
CapyFin.com Forward Guidance
Thermo Fisher plans to provide updated full-year 2025 financial guidance during the earnings call.
Positive Outlook
- Strong execution amid macroeconomic uncertainty.
- Continued innovation in AI-integrated lab technologies.
- Product launches aligned with customer demand trends.
- Increased dividend and strategic acquisitions.
- Expansion of clinical registries to support data-driven healthcare.
Challenges Ahead
- Flat year-over-year revenue growth.
- Free cash flow dropped significantly YoY.
- Slight decline in adjusted operating income.
- Revenue decline in Laboratory Products & Biopharma segment.
- Continued macroeconomic uncertainty impacting customer spending.
Revenue & Expenses
Visualization of income flow from segment revenue to net income